DE69816297T9 - Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren - Google Patents

Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren Download PDF

Info

Publication number
DE69816297T9
DE69816297T9 DE69816297T DE69816297T DE69816297T9 DE 69816297 T9 DE69816297 T9 DE 69816297T9 DE 69816297 T DE69816297 T DE 69816297T DE 69816297 T DE69816297 T DE 69816297T DE 69816297 T9 DE69816297 T9 DE 69816297T9
Authority
DE
Germany
Prior art keywords
coagulation
tissue factor
tumor
use according
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69816297T
Other languages
German (de)
English (en)
Other versions
DE69816297T2 (de
DE69816297D1 (de
Inventor
E. Philip THORPE
W. Steven KING
Boning Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas at Austin
Original Assignee
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas at Austin filed Critical University of Texas at Austin
Application granted granted Critical
Publication of DE69816297D1 publication Critical patent/DE69816297D1/de
Publication of DE69816297T2 publication Critical patent/DE69816297T2/de
Publication of DE69816297T9 publication Critical patent/DE69816297T9/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69816297T 1997-01-22 1998-01-20 Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren Active DE69816297T9 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3592097P 1997-01-22 1997-01-22
US35920P 1997-01-22
US3620597P 1997-01-27 1997-01-27
US36205P 1997-01-27
US4242797P 1997-03-27 1997-03-27
US42427P 1997-03-27
PCT/US1998/001012 WO1998031394A2 (en) 1997-01-22 1998-01-20 Tissue factor methods and compositions for coagulation and tumor treatment

Publications (3)

Publication Number Publication Date
DE69816297D1 DE69816297D1 (de) 2003-08-14
DE69816297T2 DE69816297T2 (de) 2003-12-24
DE69816297T9 true DE69816297T9 (de) 2004-09-09

Family

ID=27364921

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816297T Active DE69816297T9 (de) 1997-01-22 1998-01-20 Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren

Country Status (17)

Country Link
US (5) US6132729A (https=)
EP (1) EP0988056B1 (https=)
JP (1) JP2002514201A (https=)
KR (1) KR100565883B1 (https=)
CN (1) CN100333796C (https=)
AT (1) ATE244579T1 (https=)
AU (1) AU735187C (https=)
BR (1) BR9806793A (https=)
CA (1) CA2278106C (https=)
CY (1) CY2416B1 (https=)
DE (1) DE69816297T9 (https=)
ES (1) ES2197458T3 (https=)
IL (1) IL130908A0 (https=)
NO (1) NO323702B1 (https=)
NZ (1) NZ336720A (https=)
PT (1) PT988056E (https=)
WO (1) WO1998031394A2 (https=)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1998031394A2 (en) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
DE69941031D1 (de) * 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
DE60040981D1 (de) * 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
DK1198479T3 (da) * 1999-07-01 2008-10-13 Univ Yale Neovaskulamålrettet immunkonjugat
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
ATE488529T1 (de) * 1999-07-28 2010-12-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
WO2001016285A2 (en) 1999-08-31 2001-03-08 Novozymes A/S Novel proteases and variants thereof
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
MXPA03001984A (es) 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US7622437B2 (en) * 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
AU2002350623A1 (en) * 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7491690B2 (en) * 2001-11-14 2009-02-17 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
EP1467752A4 (en) * 2002-01-03 2005-12-07 Tanox Inc MEMBRANE PROTEINS OF EXPRESSED MASTOCYTES
WO2003070749A2 (en) * 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US20040102402A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of tissue factor expression
WO2005014775A2 (en) * 2002-06-28 2005-02-17 University Of Florida Research Foundation, Inc. Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
AU2003262760A1 (en) 2002-08-21 2004-03-11 Northwestern University Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7554021B2 (en) * 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
AU2003298647A1 (en) * 2002-11-14 2004-06-15 Claussen, Randal, C. Synthesis and self-assembly of abc triblock bola peptide
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
EP1606065A4 (en) 2003-02-11 2010-09-29 Univ Northwestern METHOD AND MATERIALS FOR NANOCRYSTALLINE SURFACE COATINGS AND ATTACHMENT OF AMPHIPHILENE PEPTIDE NANO FIBERS THEREOF
CA2519873C (en) * 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070207158A1 (en) * 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
AU2004284013A1 (en) * 2003-08-06 2005-05-06 Sirnasense As The use of siRNA silencing in the prevention of metastasis
DE10338733A1 (de) * 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
US7544661B2 (en) * 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
EP1696944A4 (en) 2003-12-05 2008-11-05 Univ Northwestern BRANCHED PEPTIDE AMPHIPHILES, RELATED EPITOPES COMPOUNDS AND SELF-ASSOCIATED STRUCTURES THEREOF
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
WO2005077333A2 (en) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Gel-based delivery of recombinant adeno-associated virus vectors
WO2005089398A2 (en) * 2004-03-18 2005-09-29 St. Luke's Hospital Method for the delivery of sustained release agents
WO2005120432A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1812032A4 (en) * 2004-10-27 2009-09-02 Univ Illinois TISSUE FACTOR COMPOSITION AND RELATED METHODS
WO2006096614A2 (en) * 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
WO2009117096A1 (en) 2008-03-19 2009-09-24 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
EP2393501A1 (en) * 2009-02-05 2011-12-14 Pierre Philippart Method and means for producing tissues and tissues obtained
MX2011010780A (es) * 2009-04-13 2011-10-28 Univ Northwestern Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso.
CN102153653B (zh) * 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
CN104387474B (zh) * 2014-11-17 2018-01-23 北京华安科创生物技术有限公司 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用
CN106699875A (zh) * 2017-02-23 2017-05-24 青岛古高生物科技有限公司 一种人重组组织因子及其基因、表达载体、宿主菌和表达方法
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
CN108948209A (zh) * 2018-07-17 2018-12-07 广西医科大学 一种cd105单链抗体-es融合蛋白的制备方法和用途
CN109999182B (zh) * 2019-03-29 2023-03-07 四川大学华西医院 凝血因子在制备抗肿瘤药物中的应用
WO2025096770A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
ES2073391T3 (es) 1986-11-04 1995-08-16 Genentech Inc Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US6001978A (en) 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
AU7050994A (en) * 1993-06-01 1994-12-20 Scripps Research Institute, The Human mutant tissue factor compositions useful as tissue factor antagonists
US5830448A (en) 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
DE69519929T2 (de) * 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US5583267B1 (en) * 1995-01-27 1998-11-24 Enzymol International Biocatalytic process for preparing tetraalkylbiphenols
US5922688A (en) 1997-01-10 1999-07-13 Board Of Regents, The University Of Texas System PEA3 is a tumor suppressor
WO1998031394A2 (en) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
AU734460B2 (en) 1997-05-22 2001-06-14 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis

Also Published As

Publication number Publication date
CN1251532A (zh) 2000-04-26
AU735187B2 (en) 2001-07-05
KR20000070389A (ko) 2000-11-25
DE69816297T2 (de) 2003-12-24
NO993567D0 (no) 1999-07-21
NO323702B1 (no) 2007-06-25
NO993567L (no) 1999-09-21
WO1998031394A3 (en) 1998-09-17
PT988056E (pt) 2003-09-30
US7951356B1 (en) 2011-05-31
JP2002514201A (ja) 2002-05-14
AU5924398A (en) 1998-08-07
IL130908A0 (en) 2001-01-28
ES2197458T3 (es) 2004-01-01
CA2278106C (en) 2005-04-12
BR9806793A (pt) 2000-05-16
CA2278106A1 (en) 1998-07-23
US6132729A (en) 2000-10-17
KR100565883B1 (ko) 2006-03-31
DE69816297D1 (de) 2003-08-14
US7101557B2 (en) 2006-09-05
CY2416B1 (en) 2004-11-12
US20030232753A1 (en) 2003-12-18
NZ336720A (en) 2001-06-29
AU735187C (en) 2002-04-18
EP0988056A2 (en) 2000-03-29
ATE244579T1 (de) 2003-07-15
US6156321A (en) 2000-12-05
WO1998031394A2 (en) 1998-07-23
US6132730A (en) 2000-10-17
EP0988056B1 (en) 2003-07-09
CN100333796C (zh) 2007-08-29

Similar Documents

Publication Publication Date Title
DE69816297T9 (de) Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
DE69519929T2 (de) Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US6004555A (en) Methods for the specific coagulation of vasculature
US6093399A (en) Methods and compositions for the specific coagulation of vasculature
US6036955A (en) Kits and methods for the specific coagulation of vasculature
US5877289A (en) Tissue factor compositions and ligands for the specific coagulation of vasculature
US7691380B2 (en) Combined methods for tumor coagulation and tumor treatment
US20030211075A1 (en) Combined compositions for tumor vasculature coagulation and treatment
JP2002520297A (ja) アミノリン脂質に結合する治療結合体を用いる癌処置方法
WO1993020848A1 (en) Immunotoxins directed against cd33 related surface antigens
MXPA99006688A (en) Tissue factor methods and compositions for coagulation and tumor treatment
HK1014496B (en) Methods and compositions for the specific coagulation of tumoral vasculature
AU2002362487A1 (en) Combined compositions and methods for tumor vasculature coagulation and treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition